AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 29, 2025.

By Elana Gotkine HealthDay Reporter

TUESDAY, April 29, 2025 -- A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR) solid tumors, according to a study published online April 27 in the New England Journal of Medicine to coincide with the annual meeting of the American Association for Cancer Research, held from April 25 to 30 in Chicago.

Andrea Cercek, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues conducted a phase 2 study involving patients with stage I, II, or III dMMR solid tumors amenable to curative-intent surgery who were treated with neoadjuvant dostarlimab, a PD-1 blocking agent, for six months. The response to treatment was assessed in cohort 1, involving 49 patients with dMMR locally advanced rectal cancer, and in cohort 2, involving 54 patients with dMMR nonrectal solid tumors. Patients with a clinical complete response could proceed with nonoperative management.

The researchers found that all 49 patients in cohort 1 who completed treatment had a clinical complete response and proceeded with nonoperative management. At 12 months, 37 had a sustained clinical complete response, which met the criterion for efficacy. A total of 35 patients in cohort 2 who completed treatment had a clinical complete response, and 33 proceeded with nonoperative management. For patients in both cohorts, recurrence-free survival at two years was 92 percent, with a median follow-up for recurrence of 20 months.

"Larger studies are needed to confirm the long-term benefit of this treatment, especially among patients with nonrectal tumors, who had a shorter median follow-up for recurrence," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including GSK, which manufactures dostarlimab and partially funded the study.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-04-30 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords